Intra-cellular Therapies, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Eduardo Rene Salas reports the disposal of Intra-Cellular Therapies shares and cancellation of stock options following the company's merger with Johnson & Johnson, where shareholders received $132 per share.
Director Riggs Rory B reports the disposal of common stock and stock options in Intra-Cellular Therapies following the company's merger with Johnson & Johnson on April 2, 2025.
Michael Halstead, President of Intra-Cellular Therapies, reports the disposal of shares and derivative securities following the merger with Johnson & Johnson, where each share was converted into $132 in cash.
Director Robert L. Van Nostrand reports the disposal of Intra-Cellular Therapies shares and derivative securities following the completion of the merger with Johnson & Johnson on April 2, 2025.
Form 4: Intra-Cellular Therapies Executive Mark Neumann Disposes of Shares in Johnson & Johnson Merger
Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, Inc., reports the disposal of shares and derivative securities following the company's merger with Johnson & Johnson.
Joel S. Marcus reports the disposition of Intra-Cellular Therapies shares and derivative securities following the company's merger with a Johnson & Johnson subsidiary at a price of $132 per share.
Following the merger of Intra-Cellular Therapies with Johnson & Johnson, CEO Sharon Mates reports the disposal of shares and derivative securities as per the merger agreement.
Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, reports the disposition of common stock, stock options, and restricted stock units due to the merger with Johnson & Johnson, where Intra-Cellular Therapies became a wholly-owned subsidiary of Johnson & Johnson.
Form 4: Intra-Cellular Therapies Executive Sanjeev Narula Disposes of Shares in Johnson & Johnson Merger
Executive Vice President & CFO of Intra-Cellular Therapies, Sanjeev Narula, reports the disposal of stock options and restricted stock units due to the merger with Johnson & Johnson, where each share was converted into $132.00 in cash.
Sharon Mates, CEO of Intra-Cellular Therapies, reports a transfer of 190,000 shares of common stock to the Sharon Mates Family Foundation as a bona fide gift.
EVP and Chief Medical Officer of Intra-Cellular Therapies, Suresh K. Durgam, reports the vesting and tax withholding of restricted stock units.
Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
EVP and Chief Commercial Officer of Intra-Cellular Therapies, Mark Neumann, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Michael Halstead, President of Intra-Cellular Therapies, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Michael Halstead, President of Intra-Cellular Therapies, reports the vesting and settlement of restricted stock units, along with associated tax withholding.
Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Form 4: Intra-Cellular Therapies Executive Exercises Stock Options, Disposes of Shares for Tax Obligations
EVP and Chief Medical Officer of Intra-Cellular Therapies, Suresh K. Durgam, reports exercising stock options and disposing of shares to cover tax obligations on March 1, 2025.
Form 4: Intra-Cellular Therapies Director Joel Marcus Reports Stock Option Exercise and Share Acquisition
Director Joel Marcus exercised stock options and acquired shares of Intra-Cellular Therapies, Inc. at a price of $63.79 per share.
Sharon Mates, CEO of Intra-Cellular Therapies, reports acquisition of shares through vested performance-based restricted stock units and withholding of shares for tax obligations.
Michael Halstead, President of Intra-Cellular Therapies, reports acquisition of shares through vested restricted stock units and disposition of shares to cover tax obligations.
EVP, Chief Commercial Officer of Intra-Cellular Therapies, Mark Neumann, reports acquisition of shares through vested performance-based restricted stock units (PRSUs) and shares withheld for tax obligations.
Form 4: Intra-Cellular Therapies EVP, Chief Medical Officer, Suresh Durgam, Reports Stock Transactions
Suresh Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, reports the vesting of performance-based restricted stock units (PRSUs) and shares withheld for tax obligations.
Executive Vice President & CFO of Intra-Cellular Therapies, Sanjeev Narula, received 22,727 restricted stock units on February 3, 2025.
Director Rory B. Riggs of Intra-Cellular Therapies, Inc. acquired 215 shares of common stock on December 31, 2024.
Intra-Cellular Therapies' CEO, Sharon Mates, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Intra-Cellular Therapies' President, Michael Halstead, executed multiple sales of company stock under a pre-arranged 10b5-1 trading plan.
Director Rory B. Riggs reports the vesting of 14,189 restricted stock units into common stock of Intra-Cellular Therapies, Inc. on June 18, 2019.
Director Rory Riggs acquired 246 shares of Intra-Cellular Therapies, Inc. at a price of $73.17 per share on September 30, 2024.
Form 4: Intra-Cellular Therapies CEO Sharon Mates Executes Stock Option and Sells Shares Under 10b5-1 Plan
Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.